Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Yale University
Mayo Clinic
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
Mayo Clinic
University of California, Irvine
Ossium Health, Inc.
National Institutes of Health Clinical Center (CC)
Essen Biotech
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
Hadassah Medical Organization
Hadassah Medical Organization
Herlev Hospital
University of Pittsburgh
Vall d'Hebron Institute of Oncology
BioEclipse Therapeutics
Sheba Medical Center